- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04205487
PrEP Readiness Interventions for Supporting Motivation (PRISM)
October 4, 2023 updated by: Adam Carrico, PhD, Florida International University
PrEP Readiness Interventions for Supporting Motivation in Stimulant-Using Sexual Minority Men
The overarching goal of this formative research is to examine whether, and in what combination, contingency management (CM) and motivational interviewing (MI) can facilitate entry of stimulant-using men who have sex with men (MSM) into the pre-exposure prophylaxis (PrEP) care continuum.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
In Stage 1, participants will be randomized to receive either: 1) three months of CM; or 2) two sessions of MI.
All participants will be assessed at three months post-randomization for non-response.
In Stage 2, a second randomization where non-responders (i.e., those who have not filled a PrEP prescription) are assigned to: 1) Switch to sequentially receive the other intervention (i.e., CM+MI or MI+CM); or 2) Continue with assessments only (i.e., CM-Only or MI-Only).
All participants will complete a final assessment at 6 months.
Study Type
Interventional
Enrollment (Actual)
70
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Adam Carrico, PhD
- Phone Number: 415-533-8653
- Email: a.carrico@miami.edu
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- At least 18 years of age
- Sexually active cisgender sexual minority man
- Reports using stimulants in the past three months
- HIV-negative serostatus
- Meets Centers for Disease Control and Prevention (CDC) criteria for PrEP eligibility
Exclusion Criteria:
- Currently prescribed PrEP
- Unable to provide informed consent
- Severe psychiatric symptoms (e.g., mania, psychosis) that impair capacity to participate
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Contingency Management (CM) - Only
CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
|
CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
|
Experimental: Motivational Interviewing (MI) - Only
Two MI sessions focusing on stimulant use, sexual risk, and PrEP use will be delivered.
|
Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.
|
Experimental: CM+MI
CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
Participants who do not fill a PrEP prescription at 3 months will then receive 2 sessions of MI.
|
CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.
|
Experimental: MI+CM
Two MI sessions focusing on stimulant use, sexual risk, and PrEP use will be delivered.
Participants who do not fill a PrEP prescription at 3 months will receive CM financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
|
CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Filling a prescription for PrEP
Time Frame: 6 Months
|
The proportion of participants who provide evidence that they have filled a PrEP prescription
|
6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-reported PrEP clinical evaluation by a medical provider
Time Frame: 6 Months
|
The proportion of participants reporting that they attended a medical appointment to be evaluated for PrEP.
|
6 Months
|
Self-reported stimulant use severity
Time Frame: 6 months
|
Participants will complete the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST), which provides validated composite scores indexing the severity of cocaine and amphetamine use (Mild = 0-3; Moderate = 4-26; Severe = 27 or greater).
|
6 months
|
Self-reported condomless receptive anal sex (Receptive CAS)
Time Frame: 6 months
|
Participants will complete a detailed behavioral assessment to report the number of men with whom they have had receptive CAS.
The proportion of participants reporting any receptive CAS will be reported.
|
6 months
|
Self-reported condomless insertive anal sex (Insertive CAS)
Time Frame: 6 months
|
Participants will complete a detailed behavioral assessment to report the number of men with whom they have had insertive CAS.
The proportion of participants reporting any insertive CAS will be reported.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Adam W Carrico, PhD, University of Miami
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 16, 2020
Primary Completion (Actual)
July 20, 2023
Study Completion (Actual)
July 28, 2023
Study Registration Dates
First Submitted
December 13, 2019
First Submitted That Met QC Criteria
December 17, 2019
First Posted (Actual)
December 19, 2019
Study Record Updates
Last Update Posted (Actual)
October 5, 2023
Last Update Submitted That Met QC Criteria
October 4, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20180823
- R34DA046367 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Contingency Management (CM)
-
VA Office of Research and DevelopmentRecruitingPTSD | Cannabis-Related DisorderUnited States
-
NYU Langone HealthNational Institute of Mental Health (NIMH)CompletedAttention Deficit Disorder With HyperactivityUnited States
-
Oregon Social Learning CenterActive, not recruiting
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)CompletedAdolescent Substance UseUnited States
-
UConn HealthNational Institute of Mental Health (NIMH)Completed
-
Yale UniversityNational Cancer Institute (NCI)Completed
-
Oregon Health and Science UniversityOregon Health Authority; Comagine HealthRecruitingMethamphetamine AbuseUnited States
-
Washington State UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
Dartmouth-Hitchcock Medical CenterNational Institute on Drug Abuse (NIDA); Johns Hopkins University; University... and other collaboratorsCompleted
-
University of OklahomaM.D. Anderson Cancer Center; National Cancer Institute (NCI); University of Florida and other collaboratorsRecruiting